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Abstract: K201 is a 1,4-benzothiazepine derivative that is a promising new drug with a strong cardioprotective effect. We 
initially discovered K201 as an effective suppressant of sudden cardiac cell death due to calcium overload. K201 is a non-
specific blocker of sodium, potassium and calcium channels, and its cardioprotective effect is more marked than those of 
nicorandil, prazosine, propranolol, verapamil and diltiazem. Recently, K201 has also been shown to have activities indi-
cated for treatment of atrial fibrillation, ventricular fibrillation, heart failure and ischemic heart disease, including action
as a multiple-channel blocker, inhibition of diastolic Ca
2+ release from the sarcoplasmic reticulum, suppression of sponta-
neous Ca
2+ sparks and Ca
2+ waves, blockage of annexin V and provision of myocardial protection, and improvement of 
norepinephrine-induced diastolic dysfunction. Here, we describe the pharmacological characteristics and clinical applica-
tions of K201. 
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INTRODUCTION 
  Ischemic heart disease, heart failure and severe arrhyth-
mia still have a poor outcome despite recent advances in 
drug therapy. These diseases interact with one another and 
consequently treatment options are often limited. In two 
large-scale clinical trials, the CAST [1] and SWORD [2] 
studies, performed to assess the effect of antiarrhythmic 
drugs on myocardial infarction, Vaughan-Williams Class Ic 
and III drugs aggravated outcome more severely than pla-
cebo and limitations of specific single-channel blockers were 
found. 
 K201  [4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-
2,3,4,5-tetrahydro-1,4-benzothiazepine monohydrochloride; 
C25H32N2O2S•HCl; MW: 461.07 (Fig. 1)] is a promising new 
drug that has cardioprotective effects. K201 was initially 
discovered by Kaneko et al. as an effective suppressant of 
sudden cardiac cell death (that is, kinetic cell death) for pre-
vention of onset of myocardial infarction [3]. Kinetic cell 
death occurs due to myofibrillar overcontraction induced by 
high intracellular calcium, but not ischemic reperfusion. We 
first established a screening system for drug discovery using 
a kinetic cell death model prepared by the Langendorff 
method. In this model, myofibrillar overcontraction due to 
excessive Ca
2+ release from the sarcoplasmic reticulum was 
induced by stimulation of epinephrine and caffeine with Ca
2+
loading. Many compounds were screened using this model, 
with the resultant discovery of K201 [3].  
  K201 is a 1,4-benzothiazepine derivative with a different 
structural scaffold from the 1,5-benzothiazepine, diltiazem, 
and is not classified as a calcium channel blocker. Rather 
than acting as a  receptor blocker, K201 blocks 1 receptors 
and intracellular Ca
2+ pathways [3] and has various actions.  
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Fig. (1). Molecular structure of K201.
The effects of K201 on the cardiovascular system have been 
studied extensively and the sites of action of K201 in mem-
branes and intracellular organs in cardiomyocytes are shown 
in Fig. (2). We note that the drug is currently referred to as 
K201 or JTV519. K201 was the original name of the com-
pound during development, whereas the drug was referred to 
as JTV519 in later clinical trials. Here, we describe the 
pharmacological characteristics and clinical applications of 
K201.  
PHARMACOLOGICAL CHARACTERISTICS OF 
K201 
1. K201 is a Multiple-Channel Blocker 
  K201 is a non-specific blocker of sodium, potassium and 
calcium channels [4-6]. The effect of K201 on membrane 
current has been studied using the whole-cell voltage-clamp 
method in isolated guinea pig ventricular myocytes [4, 5] 
and in atrial cells [6]. K201 inhibits the Na
+ current (INa) in a 
voltage- and frequency-dependent manner with IC50 values 
of approximately 1.2 and 2 M at holding potentials of -60 
and -90 mV, respectively. The time-course of INa blocking by 
K201 is slower than that of lidocaine and similar to that of 
quinidine; therefore, K201 is categorized as having “inter-
mediate” but not “fast” kinetics. 
  K201 also slightly blocks the Ca
2+ current (ICa) and the 
inwardly rectifying K
+ current (IK1) with IC50 values of 3 and 
5 M, respectively. K201 blocks the rapidly activating com-
ponent of the delayed rectified K
+ current (IKr) with an IC50
of 1.2 M [6], but not the slowly activating component (IKs)
[4-6]. Recently, Nakaya et al. [6] also showed inhibitory 
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effects of K201 on the muscarinic acetylcholine receptor-
operated K current (IKAch), and K201 inhibits the carbachol-, 
adenosine-, and GTP gamma S-induced IKAch with IC50 val-
ues of 0.12, 2.29 and 2.42 M, respectively[6].  
2. K201 Inhibits Ca
2+ Release from the Sarcoplasmic   
Reticulum 
  Calcium release from the sarcoplasmic reticulum (SR) is 
the major source of Ca
2+ required for excitation-contraction 
(EC) coupling. Membrane depolarization activates the L-
type Ca
2+ influx channel, which results in Ca
2+ influx that 
then triggers a large Ca
2+ release from the SR by opening the 
cardiac ryanodine receptor (RyR2). This mechanism is 
known as Ca
2+-induced Ca
2+ release [7].  
K201 is believed to stabilize the closed state of RyR2 by 
increasing its affinity for the 12.6 kDa FK506-binding pro-
tein (FKBP12.6), which prevents the Ca
2+ leak that triggers 
arrhythmias [8]. Protein kinase A (PKA) phosphorylation of 
RyR2 dissociates FKBP12.6 and regulates channel opening. 
In failing hearts, RyR2 is hyperphosphorylated by PKA, re-
sulting in defective channel function due to increased sensi-
tivity to Ca
2+-induced activation [8-10]. Hyperphosphoryla-
tion of RyR2 in heart failure produced by rapid right ven-
tricular pacing is reversed by K201 treatment, with a return 
to levels of channel phosphorylation seen in normal hearts. 
K201 also prevents a decrease in the amount of RyR2-bound 
FKBP12.6 in this model [11]. However, recent studies have 
shown that FKBP12.6 may not be involved in Ca
2+ release 
from the sarcoplasmic reticulum, since the loss of FKBP12.6 
has no significant effect on the conduction and activation of 
RyR2 or the propensity for spontaneous Ca
2+ release and 
stress-induced ventricular arrhythmias [12]. K201 corrects 
the defective channel gating in RyR2 and causes a rapid con-
formational change and increased Ca
2+ release in heart fail-
ure [13]. However, it is not clear if this mechanism is associ-
ated with FKBP12.6 in terms of channel stabilization of 
RyR2 [13]. In a Ca
2+ overload rat model, treatment of ven-
tricular myocytes with FK506 to dissociate FKBP12.6 from 
RyR2 did not affect the suppression of spontaneous Ca
2+
release by K201 [14].  
  The phosphorylation status of RyR2 in heart failure and 
its effect on the RyR2-FKBP12.6 interaction are controver-
sial. The PKA-dependent increase in myocyte Ca
2+ spark 
frequency and size is entirely attributable to phospholamban 
phosphorylation and consequent enhanced SR Ca
2+ loading, 
and PKA does not seem to have any appreciable effects on 
resting RyR2 function in ventricular myocytes [15]. In car-
diac SR vesicles, K201 restores the conformational change 
and corrects defective channel gating in RyR2 independent 
of phosphorylation of RyR2 [13]. FKBP12.6 dissociates 
from RyR2 due to PKA phosphorylation or FK506-induced
domain unzipping, and this causes Ca
2+ leak. K201 reverses 
this domain unzipping and stops Ca
2+ leak completely, even 
after FKBP12.6 has mainly dissociated from RyR2 due to 
hyperphosphorylationof RyR2 [16].  
Fig. (2). Action sites of K201 on the cell membrane and in cells: , inhibition; , activation; , modulation. AC: adenylate cyclase, Ach: 
acetylcholine, An V: annexin V, AR: adrenoreceptor, Epi: epinephrine, FKBP: FK506 binding protein, G: G-protein, MLC: myosin light 
chain, M2-Rec: M2-muscarinic receptor, NCX: Na
+/Ca
2+ exchanger, PKA: protein kinase A, PKC: protein kinase C, PLB: phospholamban, 
PLC: phospholipase C, PS: phosphatidylserine, NE: norepinephrine, RACK: receptor for activated C kinase, RyR2: ryanodine receptor 2, 
SR: sarcoplasmic reticulum, SERCA: SR Ca
2+-ATPase, Tn: troponin. 128 Current Clinical Pharmacology, 2009, Vol. 4, No. 2 Kaneko et al. 
3. K201 Suppresses Spontaneous Ca
2+ Sparks (Ca
2+ leak) 
and Ca
2+ Waves  
  In heart muscle, local elevations in intracellular calcium 
(Ca
2+ sparks) are elementary SR Ca
2+-release events. A Ca
2+ 
spark is a local Ca
2+ release from the SR that also occurs in 
normal ventricular myocytes. Ca
2+  spark accumulation 
propagates to an adjacent SR as a Ca
2+ wave, with conse-
quent induction of Ca
2+-induced Ca
2+ release [17, 18]. In the 
48-hour infarcted canine heart, abnormal Ca
2+ wave activity 
is the underlying cause of afterdepolarization-induced elec-
trical activity in surviving subendocardial Purkinje cells. 
Drugs that block inward sodium or calcium currents (vera-
pamil, tetrodotoxin) have no effect on Ca
2+ activity in Purk-
inje cells, but K201 strongly suppresses spontaneous Ca
2+ 
release in Purkinje cells dispersed from the subendcardium 
of the infarct zone (IZPCs) [19]. Agents that block or inhibit 
intracellular Ca
2+ channel activity and reduce Ca
2+ waves can 
have antiarrhythmic effects in arrhythmogenic Purkinje cells 
in the infarcted heart [19]. K201 at 1 mol/L reduces the 
frequency of spontaneous Ca
2+ release and the frequency and 
velocity of SR Ca
2+ waves, despite the absence of a change 
in SR Ca
2+ content, and also reduces Ca
2+ spark amplitude 
and frequency and inhibits SR Ca
2+ uptake and release. K201 
inhibits spontaneous diastolic Ca
2+ release during Ca
2+ over-
load by a dual inhibitory action on sarcoplasmic reticulum 
Ca
2+-ATPase (SERCA2a) and RyR2, without significantly 
affecting the transient Ca
2+ amplitude [20].  
4. K201 Blocks Annexin V and Provides Myocardial   
Protection  
  Annexin V is a member of the annexin family of Ca
2+-
binding proteins that have activity that depends on the Ca
2+
concentration. In vitro, annexin V binding to F-actin depends 
on the calcium concentration and the presence of phosphati-
dylserine, a membrane phospholipid [21-23]. K201 inhibits 
the interaction between these two proteins, whereas dilti-
azem and KT362 do not inhibit this binding [3]. Annexin V 
is distributed in various organs and cells and is involved in 
processes including fusion, development and differentiation. 
This protein induces calcium channel activity, as shown by 
patch-clamping, and is critical in cellular signaling. The 
crystal structure of annexin V bound to K201 shows that the 
drug binds in the Ca
2+ “hole” of annexin V (Fig. 3) [24]. 
K201 binds in an L-shaped conformation at the hinge region 
cavity formed by the N-terminal strand and domains II, III 
and IV, on the side opposite to the calcium and membrane-
binding surface (Fig. 4(a),(b)). K201 may restrain the hinge 
movement of annexin V in an allosteric manner, resulting in 
inhibition of calcium movement across the annexin V mole-
cule [24]. We have shown that annexin V activates Ca
2+
channels and K201 inhibits this Ca
2+ influx in an artificial 
lipid membrane. Annexin V also induces Ca
2+ channel activ-
ity in large unilamellar vesicles (LUVs) and K201 shows 
dose-dependent inhibition of annexin V-induced inward Ca
2+
movement into LUVs [25].
  A recent study has shown a similarity of the amino-acid 
sequences of RyR2 and annexin V: the K201 binding site in 
annexin is present as domain 2114-2149 of RyR2, and do-
main 2059-2156 of RyR2 showed a striking similarity to the  
corresponding sequence of annexin V [26]. Interruption of 
the interdomain interaction between domain 2114-2149 and 
the central domain 2234-2750 seems to mediate stabilization 
of RyR2 in failing hearts, and K201 inhibition of Ca
2+ leak-
age does not depend on the facilitated binding of FKBP12.6 
to RyR2 [26]. Another recent study has shown that annexin 
V has a site homologous to the  protein kinase C (PKC)-
binding protein RACK (receptor for activated C kinase). The 
RACK-like sequence in annexin V is in close proximity to 
the K201 binding site on annexin V, which indicates the po-
tential importance of the RACK-like sequence in annexin V 
for PKC binding. PKC binding to annexin V activates 
PKC translocation, and therefore K201 may inhibit PKC 
activity [27]. 
5. K201 Improves Norepinephrine-Induced Diastolic 
Dysfunction 
  We have shown that norepinephrine with Ca
2+ loading 
induces severe diastolic dysfunction [28]. Under these condi-
tions, a diastolic pressure equivalent to the systolic pressure 
is induced without membrane depolarization. The left ven-
tricular diastolic pressure is markedly increased and the dia-
stolic pressure exceeds the aortic pressure, resulting in open-
ing of the aortic valve in the diastolic phase (Fig. 5) [28]. 
K201 significantly inhibits norepinephrine-induced diastolic 
dysfunction whereas diltiazem has no suppressive effect 
[29]. Norepinephrine administration in old myocardial in-
farction rats induces similar diastolic dysfunction. An intra-
cellular Ca
2+ increase in the diastolic phase is an important 
factor in development of diastolic dysfunction, but it has also 
been reported that an intracellular Ca
2+ increase in the dia-
stolic phase alone does not increase the left ventricular end-
diastolic pressure [30].
Fig. (3). The crystal structure of annexin V and binding site of 
K201. The K201 molecule is shown as a space-filling model. Hinge 
regions are represented in yellow and domains I, II, II and IV are 
colored dark blue, magenta, orange and sky-blue, respectively [24]. Pharmacological Characteristics and Clinical Applications of K201  Current Clinical Pharmacology, 2009, Vol. 4, No. 2   129
CLINICAL APPLICATIONS OF K201 
1. Inhibition of Atrial Fibrillation 
  K201 inhibits carbachol-induced atrial fibrillation in 
guinea pig atrial muscle [6]. An increase in IKAch and IKr in
atrial muscle cells is a potential mechanism for atrial fibrilla-
tion, and IKAch is often generated in the sinus node and 
atrium, and particularly in the atrial appendage of the atrium. 
K201 directly inhibits IKAch [6] and also inhibits the atrial IKr
with an IC50 of 0.41 M. Therefore, K201 is thought to im-
prove atrial fibrillation by inhibiting IKAch and IKr [6], and has 
been shown to inhibit experimental atrial fibrillation in a dog 
aseptic pericarditis model [31].  
  Abnormal calcium homeostasis with ryanodine receptor 
dysfunction may underlie arrhythmogenic activity in pulmo-
nary veins. Both pretreatment and rapid administration of 
K201 (0.3 M) decrease isoproterenol-induced arrhyth-
mogenesis in pulmonary veins through reduction of the ar-
rhythmogenic activity of pulmonary vein cardiomyocytes. 
These findings indicate the anti-arrhythmic potential of K201 
[32]. 
2. Inhibition of Ventricular Tachycardia and Fibrillation 
  Triggered activity is a major cause of arrhythmias, in 
addition to abnormal automaticity and reentry. Triggered 
activity is classified into early after depolarization (EAD), a 
transient depolarization that is generated immediately after 
or from the second or third phase of the preceding action 
potential; and delayed after depolarization (DAD) generated 
from the fourth phase of the preceding action potential. EAD 
develops due to a prolonged duration of the action potential 
and DAD is induced by an abnormal increase in intracellular 
Ca
2+. Classic antiarrhythmic drugs tend to inhibit cardiac 
function and induce arrhythmia. The class III drug clofilium 
prolongs QT and induces torsades de pointes (Tdp) and ven-
tricular tachycardia when combined with an 1-adrenoceptor 
stimulator, due to EAD generated from the third phase of the 
action potential [33-35]. We have shown that K201 inhibits 
clofilium-induced Tdp and attenuates the prolongation of 
repolarization caused by clofilium. Our results show that 
K201 causes prolongation of the QT and QTc intervals, but 
does not induce Tdp, in the presence or absence of 1-
adrenoceptorstimulation. The inhibition of clofilium-induced 
Fig. (4). Amino acids of annexin V in the vicinity of bound K201. (a) The L-shaped K201 molecule interacts at the hinge 2 region. (b) The 
K201 binding site in stereo view [24]. 130 Current Clinical Pharmacology, 2009, Vol. 4, No. 2 Kaneko et al. 
Tdp by K201, despite QT prolongation, suggests that QT 
prolongation alone is not a proarrhythmic signal. K201 sup-
presses Tdp dose-dependently by blocking the 1-adreno-
ceptor and inhibiting abnormal Ca
2+ release from the SR 
[36]. 
3. Improvement of Diastolic Heart Failure 
  Diastolic dysfunction refers to an abnormality in diastolic 
distensibility, filling, and relaxation of the left ventricle [37, 
38]. The onset mechanism of this type of heart failure, (so-
called diastolic heart failure) is unknown. Systolic heart fail-
ure can be treated with digitalis and catecholamines that en-
hance myocardial contractility, but there are no drugs for 
treatment of diastolic heart failure. We have reported that 
norepinephrine induces a marked increase in left ventricular 
end-diastolic pressure in rats with Ca
2+ loading or old myo-
cardial infarction [28]. K201 significantly suppressed the 
increase in left ventricular end-diastolic pressure, decreased 
the incidence of norepinephrine-induced diastolic contrac-
ture, including aortic value opening in the diastolic phase, 
and improved Ea and deceleration time in cardiac Doppler 
ultrasonography. These results suggest that K201 may be an 
agent for treatment of diastolic heart failure [11, 29, 39]. 
4. Cardioprotective Effects Against Myocardial Injury  
  K201 was initially developed as a drug that prevents on-
set of myocardial infarction and sudden cardiac death. K201 
provides myocardial protection more effectively than exist-
ing calcium channel blockers and  blockers and is less 
negatively inotropic and chronotropic [3]. K201 inhibits 
ischemia/reperfusion injury dose-dependently [40] and 
blocks (Takotsubo) stress cardiomyopathy induced by large 
amounts of isoproterenol (5 mg/kg) [41]. K201 also has a 
cardioprotective effect against myocardial injury that is 
stronger than those of nicorandil, prazosin, propanolol, vera-
pamil and diltiazem [3]. These results indicate that K201 can 
prevent myocardial injury caused by ischemia and catecho-
lamines. 
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